The two studies were part of larger project aimed at building a complete map of mitochondrial function and associated proteins.
The results support a survival benefit for patients treated with therapies guided by combined DNA and mRNA sequencing and protein expression analyses.
The assay is designed to measure changes in blood levels of the peptide precursor procalcitonin to differentiate bacterial infections from viral ones.
Researchers also uncovered key pathways and alterations linked to differences in survival.
Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.
The Swiss firm's assay combines a 29-gene host immune response panel with two tumor-derived proteins to detect early-stage colorectal cancer and large adenomatous polyps.
The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.
The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
The company said it plans to launch a clinical trial to validate its Immray PanCan-d blood test in both Europe and the US.
While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.
The decision lets Vermillion access Medi-Cal's patient network, which covers more than 12.6 million lives, or roughly a third of California's covered lives.
In a large, prospective study published in Lancet Oncology, the screening assay was projected to reduce the number of prostate biopsies by 32 percent.
The company presented new data at a meeting last week showing that Vectra DA predicted whether patients would do better on one or the other of two possible second-line therapies.
The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.
The deal provides Sciex with the rights to commercialize immune-MRM technology developed by Amanda Paulovich's laboratory.
OncoPlex operates a CAP-accredited and CLIA-certified laboratory and provides mass spectrometry-based tumor profiling services.
The funding will be used to further expand the company's clinical testing products and services in the US and abroad.
Using a self-similar chain-based device combined with Raman spectroscopy, they were able to detect the BRCA1 missense mutation M1775R at picomolar levels.
The investment bank has a $4 price target on Vermillion's stock and noted the firm's OVA2 test, a change to its relationship with Quest, and new management.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.